PerkinElmer spends $5.3B on its fourth acquisition this year
Life sciences giant PerkinElmer Inc. (NYSE: PKI) is making yet another acquisition, this time the biggest one in its history, buying San Diego, Calif.-based BioLegend for $5.25 billion in cash and stock. Goldman Sachs provided bridge financing for the deal. The transaction marks PerkinElmer's fourth such deal since the beginning of May. The Waltham company recently acquired SIRION Biotech GmbH, a German provider of viral vector-based technologies for use in cell and gene therapies, for an undisclosed… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 26, 2021 Category: American Health Authors: Rowan Walrath Source Type: news

Catalent Launches New OptiDose ® Design Solution to Help Create...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb July 26, 2021)Read the full story at https://www.prweb.com/releases/catalent_launches_new_optidose_design_solution_to_help_create_differentiated_treatments_that_are_successful_for_innovators_patients_and_health_care_professionals/prweb18092608.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 26, 2021 Category: Pharmaceuticals Source Type: news

Targeted gene therapy may protect against vision loss from glaucoma, diabetes, study says
A new form of gene therapy may help prevent vision loss caused by diabetic retinopathy and glaucoma, according to a study published Thursday by the journal Cell. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 22, 2021 Category: Consumer Health News Source Type: news

Scientists discover gene therapy provides neuroprotection to prevent glaucoma vision loss
An NIH-funded research project found that calcium modulator CaMKII protects the optic nerve in mice, opening the door to new sight-saving therapy. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - July 22, 2021 Category: American Health Source Type: news

Catalent Biologics Launches New GPEx ® Lightning Cell Line...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb July 22, 2021)Read the full story at https://www.prweb.com/releases/catalent_biologics_launches_new_gpex_lightning_cell_line_expression_technology_to_shorten_drug_substance_development_timelines_by_up_to_three_months/prweb18085546.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 22, 2021 Category: Pharmaceuticals Source Type: news

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform
Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases Funding led by Seroba Life Sciences and supported by Théa Open Innovation, eureKARE and e... Biopharmaceuticals, Venture Capital Coave Therapeutics, gene therapy, AAV-Ligand Conjugate, ALIGATER (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 21, 2021 Category: Pharmaceuticals Source Type: news

G-CON Manufacturing, the leading US-based provider of POD ® ...
Through its acquisition of G-CON, Summa Equity enters the rapidly growing biopharmaceutical manufacturing market, including cell and gene therapy manufacturing.(PRWeb July 20, 2021)Read the full story at https://www.prweb.com/releases/g_con_manufacturing_the_leading_us_based_provider_of_pod_cleanroom_solutions_is_acquired_by_summa_equity/prweb18080487.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 20, 2021 Category: Pharmaceuticals Source Type: news

Gene therapy developer Passage Bio adds a trio to its C-suite
The new hires include a CFO and chief medical officer. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 19, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

RNA modification may protect against liver disease, explain liver fat differences between sexes
FINDINGSA chemical modification that occurs in some RNA molecules as they carry genetic instructions from DNA to cells ’ protein-making machinery may offer protection against non-alcoholic fatty liver, a condition that results from a build-up of fat in the liver and can lead to advanced liver disease, according to a new study by UCLA researchers.The study, conducted in mice, also suggests that this modification — known as m6A, in which a methyl group attaches to an RNA chain — may occurat a different ratein femalesthan it does inmales, potentially explaining why females tend to have higher fat content in ...
Source: UCLA Newsroom: Health Sciences - July 19, 2021 Category: Universities & Medical Training Source Type: news

RTP newcomer raises $100M to advance gene therapy platform
The California-based company has raised at least $180 million since 2020. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 19, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

Chance That COVID-19 Vaccines Are Gene Therapy?
'Zero'(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 19, 2021 Category: General Medicine Source Type: news

Chance That COVID 19 Vaccines Are Gene Therapy
Chance That COVID-19 Vaccines Are Gene Therapy?'Zero'(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 19, 2021 Category: General Medicine Source Type: news

Chance That COVID-19 Vaccines Are Gene Therapy?'Zero'Chance That COVID-19 Vaccines Are Gene Therapy?'Zero '
Much of the misinformation surrounding vaccines from Pfizer and Moderna involve fear that they will alter our genes. But the science shows there is"zero" chance of that happening.WebMD Health News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 17, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

What's the Chance That COVID-19 Vaccines Are Gene Therapy?'Zero'What's the Chance That COVID-19 Vaccines Are Gene Therapy?'Zero '
Much of the misinformation surrounding vaccines from Pfizer and Moderna involve fear that they will alter our genes. But the science shows there is"zero" chance of that happening.WebMD Health News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 16, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

NIH-funded study finds gene therapy may restore missing enzyme in rare disease
Results provide hope for children with aromatic L-amino acid decarboxylase deficiency. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - July 16, 2021 Category: American Health Source Type: news

NIH-funded study finds gene therapy may restore missing enzyme in rare disease
(NIH/National Institute of Neurological Disorders and Stroke) A new study published in Nature Communications suggests that gene therapy delivered into the brain may be safe and effective in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare neurological disorder that develops in infancy and leads to near absent levels of certain brain chemicals, serotonin and dopamine, that are critical for movement, behavior, and sleep. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2021 Category: International Medicine & Public Health Source Type: news

A fast-growing cell therapy company snagged a big Fremont manufacturing space
Cell therapy and gene therapy companies have gobbled more than a half-billion square feet of manufacturing space in the Bay Area over the past year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 14, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

A fast-growing cell therapy company snagged a big Fremont manufacturing space
Cell therapy and gene therapy companies have gobbled more than a half-billion square feet of manufacturing space in the Bay Area over the past year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 14, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Another fast-growing cell therapy company snags big East Bay manufacturing space
Cell therapy and gene therapy companies have gobbled more than a half-billion square feet of manufacturing space in the Bay Area over the past year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 14, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Another fast-growing cell therapy company snags big East Bay manufacturing space
Cell therapy and gene therapy companies have gobbled more than a half-billion square feet of manufacturing space in the Bay Area over the past year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 14, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Catalent Signs Agreement with JOS Pharmaceuticals to Develop...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb July 13, 2021)Read the full story at https://www.prweb.com/releases/catalent_signs_agreement_with_jos_pharmaceuticals_to_develop_fast_dissolve_zydis_formulation_for_cannabidiol_as_an_anesthesia_premedication/prweb18064406.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 13, 2021 Category: Pharmaceuticals Source Type: news

Scrap taxes on drug import for spinal muscular atrophy, Stalin tells Centre
For children affected by SPA, gene-therapy has to be ideally given before the child reaches two years of age and this therapy costs over Rs 16 crore per person, Stalin said in a letter to union finance minister Nirmala Sitharaman. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 13, 2021 Category: Pharmaceuticals Source Type: news

Gene therapy offers long-awaited hope for children with rare, incurable disorder
(University of California - San Francisco) Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children's Hospitals. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2021 Category: International Medicine & Public Health Source Type: news

Baby gets go-ahead for world ’s most expensive drug from NHS
NHS approved to use gene therapy to treat baby born with spinal muscular atrophyThe parents of a baby with a fatal condition have succeeded in their campaign for their son to be treated with the world ’s most expensive drug.A new gene therapy, Zolgensma, will be used to treat 10-month-old Edward, from Colchester, who has severe spinal muscular atrophy (SMA), after his parents were given the green light earlier this week. The genetic condition, which is caused by a missing protein, weakens the muscles and affects movement and breathing.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 11, 2021 Category: Science Authors: Clea Skopeliti Tags: NHS Medical research Health Society Science UK news Source Type: news

Revisionist historians "cancel" Dr. Robert Malone, creator of mRNA technology in latest memory hole PURGE of truth
(Natural News) The man behind mRNA (messenger RNA) “vaccine” technology is being scrubbed from the digital history books for daring to publicly speak out about its dangers. Dr. Robert Malone appeared on a recent episode of the DarkHorse podcast to explain that experimental Wuhan coronavirus (Covid-19) gene therapy – this is what the jabs are,... (Source: NaturalNews.com)
Source: NaturalNews.com - July 7, 2021 Category: Consumer Health News Source Type: news

NIDCR Science News - July 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. Mimicking Mother Nature to Grow a Gland New video shows how scientists achieved first key step in growing an artificial salivary gland NIDCR • July 2, 2021 A Four-Decade Quest to Uncover a Molecular Secret Scientist's lifelong research could hold clues to brain disorders, cancer NIDCR • June 21, 2...
Source: NIDCR Science News - July 6, 2021 Category: Dentistry Source Type: news

Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
Basel, 02 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, from 17-21 July 2021. Data will include the final analysis from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group).1,2 (Source: Roche Media News)
Source: Roche Media News - July 2, 2021 Category: Pharmaceuticals Source Type: news

Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
Basel, 02 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, from 17-21 July 2021. Data will include the final analysis from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group).1,2 (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2021 Category: Pharmaceuticals Source Type: news

Pig Study Could Lead to Gene Therapy to Prevent Heart Failure
Title: Pig Study Could Lead to Gene Therapy to Prevent Heart FailureCategory: Health NewsCreated: 7/1/2021 12:00:00 AMLast Editorial Review: 7/2/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 2, 2021 Category: Cardiology Source Type: news

Pig Study Could Lead to Gene Therapy to Prevent Heart Failure
THURSDAY, July 1, 2021 -- A gene therapy aimed at freeing the heart's capacity for self-repair has shown early promise in an animal study. The study -- done in pigs -- found that the treatment approach was not only feasible, but also improved the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 1, 2021 Category: General Medicine Source Type: news

NIDCR's Summer 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Summer 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR to Release Report on Oral Health in America As a 20-year follow-up to the seminal Oral Health in America: A Report of the Surgeon General, NIDCR will release Oral Health in America: Advances and Challenges in the fall of 2021. The report will illuminate new directions...
Source: NIDCR Science News - July 1, 2021 Category: Dentistry Source Type: news

Rockville's Vigene Biosciences closes $292M deal to be acquired
Charles River Laboratories International Inc. (NYSE: CRL) said Tuesday morning it had completed its acquisition of Vigene Biosciences Inc., a Rockville firm that helps gene therapy and vaccine companies develop and manufacture products for rare diseases. Massachusetts-based Charles River paid $292.5 million for Vigene, and it said the purchase price could include up to $57.5 million in additional payments contingent on future performance. When the deal was first announced in May, Charles River… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 29, 2021 Category: Pharmaceuticals Authors: Drew Hansen Source Type: news

Rockville's Vigene Biosciences closes $292M deal to be acquired
The firm helps gene therapy and vaccine companies develop and manufacture products for rare diseases. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 29, 2021 Category: Pharmaceuticals Authors: Drew Hansen Source Type: news

New components for antisense gene therapy show promise in treating spinal muscular atrophy
(Skolkovo Institute of Science and Technology (Skoltech)) Skoltech researchers and their colleagues from Russia and the UK investigated the safety and efficacy of new chemistry in antisense oligonucleotides used to treat spinal muscular atrophy (SMA), a debilitating genetic disease.The new findings will help develop drugs with less toxicity and fewer injections needed thanks to prolonged action. Nusinersen, an approved drug for the treatment of SMA, is administered several times a year via an injection into the spinal canal, so fewer injections would improve the quality of life for patients with SMA. (Source: EurekAlert! -...
Source: EurekAlert! - Medicine and Health - June 29, 2021 Category: International Medicine & Public Health Source Type: news

Gene therapy breakthrough offers hope to children with rare and fatal brain disease
(University College London) Scientists and doctors at UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) and Great Ormond Street Hospital (GOSH) have given hope of a gene therapy cure to children with a rare degenerative brain disorder called Dopamine Transporter Deficiency Syndrome (DTDS). The team have recreated and cured the disease using state-of-the-art laboratory and mouse models of the disease and will soon apply for a clinical trial of the therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 29, 2021 Category: International Medicine & Public Health Source Type: news

What Types of New Therapies are Available for Cystic Fibrosis?
Discussion Cystic fibrosis (CF) was identified in 1938 by Dr. Dorothy Andersen who described 49 patients with pancreatic insufficiency. Since that time significant achievements in the knowledge about the disease and treatments for patients have changed the mortality from a few months to patients living into middle adulthood or even later. Quality of life for patients and their families and friends has also markedly improved. CF is the classic Mendelian autosomal recessive genetic disorder which is a worldwide disorder but affects people of north European ancestry more often where the main mutation is more common. There are...
Source: PediatricEducation.org - June 28, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb June 24, 2021)Read the full story at https://www.prweb.com/releases/catalent_to_acquire_rheincell_therapeutics_strengthening_a_path_towards_industrialization_of_induced_pluripotent_stem_cell_based_therapies/prweb18028966.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 24, 2021 Category: Pharmaceuticals Source Type: news

Stanford spinout's latest deal looks to unlock new fix for sickle cell disease
The initial Stanford research, studying how to make more bone marrow more receptive to gene therapies and stem cell transplants and less toxic for patients, was backed by nearly $23 million in grants from California's stem cell research funding agency. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 21, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
SINGAPORE, June 18, 2021 -- (Healthcare Sales & Marketing Network) -- Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round. ... Biopharmaceuticals, Cardiology, Venture Capital Nuevocor, dilated cardiomyopathy, cardiomyopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 18, 2021 Category: Pharmaceuticals Source Type: news

Gene therapy firm bulks up C-suite with industry veteran
A California cell and gene therapy company is continuing its expansion. This time by hiring an industry veteran to its ranks. Kriya Therapeutics announced Tuesday it has added a chief medical officer to its team to lead the company's clinical and medical organization, particularly in growing its pipeline of diverse gene therapy candidates across various therapeutic areas. That executive is Ilise Lombardo. "Ilise brings a wealth of experience having led large-scale programs in large diseases, as… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 16, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

Gene therapy firm bulks up C-suite with industry veteran
A California cell and gene therapy company is continuing its expansion. This time by hiring an industry veteran to its ranks. Kriya Therapeutics announced Tuesday it has added a chief medical officer to its team to lead the company's clinical and medical organization, particularly in growing its pipeline of diverse gene therapy candidates across various therapeutic areas. That executive is Ilise Lombardo. "Ilise brings a wealth of experience having led large-scale programs in large diseases, as… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 16, 2021 Category: Biotechnology Authors: Sonia Waraich Source Type: news

2nd progressive vision loss drug by Biogen fails in late-stage trial
Another gene therapy for progressive vision loss developed by Biogen Inc. (Nasdaq: BIIB) has failed in a late-stage clinical trial, the company announced Monday. The drug, designed to target the rare genetic blindness disorder choroideremia, did not show significant benefit 12 months after treatment in a Phase 3 study involving 169 men with the disease. Biogen says it will evaluate the complete dataset before deciding on next steps for the drug's developme nt. This is the second failure in as many… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 14, 2021 Category: American Health Authors: Rowan Walrath Source Type: news

Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 14, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

Pfizer cut corners, slashed quality standards to produce covid vaccine at "warp speed"
(Natural News) The website TrialSite News has obtained eye-opening documents showing that pharmaceutical giant Pfizer cut corners and slashed quality standards to rush its Wuhan coronavirus (Covid-19) vaccine into production at “warp speed.” Pfizer and its German partner BioNTech failed to thoroughly examine biodistribution and pharmacokinetics issues related to their experimental gene therapy injection prior... (Source: NaturalNews.com)
Source: NaturalNews.com - June 11, 2021 Category: Consumer Health News Source Type: news

OHSU's potential new approach to gene therapy lurks in your medicine chest
A researcher has come up with a novel approach to disease-causing mutations using a common drug. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 11, 2021 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

OHSU's potential new approach to gene therapy lurks in your medicine chest
A researcher has come up with a novel approach to disease-causing mutations using a common drug. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 11, 2021 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

Lowell biotech brings in $23M for CNS gene therapy
After about a decade in operation, Alcyone Therapeutics is finally emerging from stealth with $23 million as it prepares its gene therapy programs for the clinic. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 10, 2021 Category: American Health Authors: Rowan Walrath Source Type: news

Advancing manufacture of cell and gene therapies webinar
(Engineering Conferences International) As part of the build-up for the ECI Advancing Manufacture of Cell and Gene Therapies conference that will be held in San Diego in February 2022, we are pleased to be hosting a special webinar to look at some of the key challenges facing our industry as we continue to grow and develop, providing a glimpse into some of the focus areas of the 2022 in-person conference. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 9, 2021 Category: Biology Source Type: news

Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 8, 2021 Category: Pharmaceuticals Authors: Sonia Waraich Source Type: news

Bayer-to-advance-two-first-of-its-kind-cell-and-gene-therapies-for-Parkinsons-disease
Parkinson’s disease is most common neurodegenerative movement disorder / It impacts more than 10 million people worldwide/ No function-restoring therapy is currently available / Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials (Source: Bayer Company News)
Source: Bayer Company News - June 8, 2021 Category: Pharmaceuticals Source Type: news